Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

STEMI Versus NSTEMI: Clinical and Angiographic Differences

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferrara Liberato Aldo, Federico II University
ClinicalTrials.gov Identifier:
NCT01636427
First received: July 6, 2012
Last updated: July 17, 2012
Last verified: July 2012

July 6, 2012
July 17, 2012
January 2007
May 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01636427 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
STEMI Versus NSTEMI: Clinical and Angiographic Differences
STEMI Versus NSTEMI: a Mono Versus a Multivessel Disease?

The purpose of this study is to assess differences in the risk profile and in the coronary angiographic presentation between STEMI and NSTEMI. Moreover possible relationship between myocardial infarction presentation and renal function will be investigated.

Assessment of risk profile. Diabetes mellitus diagnosed when fasting blood glucose (FBG) was >= 126mg/dL or if patients were taking oral hypoglycaemic drugs or were on insulin treatment. Hypertension defined as blood pressure >= 140/90 mmHg or history of antihypertensive treatment. Hypercholesterolemia,adjudicated when cholesterol levels were >= 200 mg/dL or with patients on lipid lowering treatment. Hypertriglyceridemia adjudicated on fasting triglyceride levels>= 200 mg/dL or triglyceride-lowering therapy . Obesity, defined as BMI >= 30 kg/m2.

Patients with STEMI, who had not been previously treated with thrombolysis, and those who had been undergone to an unsuccessful thrombolysis, as well as patients with NSTEMI with a TIMI score> 3 who were immediately referred to the Cat Lab and whenever possible treated with PTCA and stenting of the culprit lesion. The other patients who were referred to Cat Lab within 48 hours from the beginning of chest pain, unless their general conditions did not strongly suggest to delay the procedure after 2 more days.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients with acute myocardial infarction with or without ST segment elevation.

Acute Coronary Syndrome
Not Provided
Not Provided
Ferrara LA, Russo BF, Gente R, Esposito G, Rapacciuolo A, de Simone G. STEMI and NSTEMI: a mono versus a multivessel disease? Int J Cardiol. 2013 Oct 3;168(3):2905-6. doi: 10.1016/j.ijcard.2013.03.154. Epub 2013 May 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients admitted in the coronary care unit (CCU) of the Department of Clinical and Experimental Medicine at the Federico 2nd University Hospital;
  • Patient with indication to angiographic study even if not immediately;
  • Patients referred to CCU with the diagnosis of acute myocardial infraction (AMI), type STEMI, or NSTEMI, based on pre-admission assessment of troponin I (TpI) and myocardial band creatin kinase (CK-MB;
  • Diagnosis of NSTEMI/STEMI performed according to standard criteria

Exclusion criteria:

  • Patients who could not undergo angiographic study
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT01636427
001
No
Ferrara Liberato Aldo, Federico II University
Federico II University
Not Provided
Study Director: Giovanni de Simone, MD Federico 2nd University of Naples
Federico II University
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP